Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.

ABSTRACT:

Background

Methamphetamine-associated pulmonary arterial hypertension (Meth-PAH) represents a growing subset of PAH. Relative to idiopathic PAH (iPAH), it is unknown whether patients with Meth-PAH treated with continuous prostacyclin have similar outcomes and treatment response. The aims of this analysis are to evaluate survival, response to therapy, and right ventricle function in similarly treated patients with Meth-PAH and iPAH.

Methods

A prospective protocolized cohort of 138 incident patients (64 Meth-PAH, 74 iPAH) was followed longitudinally, with all patients being treatment-naïve at baseline. Hemodynamic assessments, cardiac imaging, and response to therapy were evaluated. A standardized therapeutic approach involving parenteral subcutaneous treprostinil was applied.

SUBMITTER: Uhland C 

PROVIDER: S-EPMC12684484 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature